dr. cella discusses axitinib and sorafenib axis trial
Published 13 years ago • 334 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:20
dr. cella on the side effect focus of the axitinib and sorafenib trial
-
1:05
dr. cella on the value of patient-reported outcomes
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:44
dr. cella on patient-reported outcomes in a clinical setting
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
0:38
dr. rini explains the axitinib integration process
-
0:51
dr. cella explains the increase in quality of life assessments
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
6:51
hcc: use of lenvatinib and sorafenib
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
2:07
haas: sorafenib/sunitinib for unfavorable rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc